ZYMEWORKS INC. (ZYME)
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (79%) **Content type:** Clinical